by Melissa Taylor, MD, MPH; Sarah Westvold, MPH; Jessica B. Long, MPH; Terry Hyslop, PhD, et al.
Summary: Cancer Fitness by Jay K. Harness, MD, FACS
This large SEER–Medicare cohort study examined more than 53,000 long-term survivors of breast, prostate, and colorectal cancers to identify who is most at risk for late-onset depression—defined as depression developing 5–10 years after cancer diagnosis, well beyond active treatment. The study excluded anyone with prior depression and analyzed demographic, treatment, and medical factors associated with new depressive symptoms. This focus on the survivorship window is clinically important: emotional and physical consequences of cancer often persist, and depression emerging years later is both common and underrecognized.
Across cancer types, late-onset depression occurred in 10.6% of survivors, with the highest risk in breast cancer (13.3%), followed by colorectal (11.8%) and prostate cancer survivors (8.7%). Several consistent predictors emerged. The strongest was a history of anxiety, which nearly tripled the risk in prostate cancer survivors and doubled it in breast and colorectal survivors. Comorbidity burden was another powerful factor: having three or more chronic conditions increased depression risk by 33–79%, highlighting the cumulative psychological load of multimorbidity in older adults.
Socioeconomic vulnerability—measured by Medicare–Medicaid dual eligibility—was a robust, cross-cancer predictor, raising depression risk by 25–38%. This underscores how financial stress, fragmented care, and reduced access to mental-health services continue to affect outcomes long after cancer treatment has ended. Notably, survivors living in high-poverty neighborhoods (particularly with breast cancer) also had higher risk.
Treatment factors were relevant mainly in men with prostate cancer. Radiotherapy, and especially radiotherapy combined with androgen deprivation therapy (ADT) for more than six months, significantly increased depression risk. This aligns with known hormonal and quality-of-life effects of ADT, including fatigue, sexual dysfunction, and metabolic changes that can contribute to mood disturbances. In contrast, cancer stage, tumor characteristics, and treatment in breast or colorectal cancer were not independently associated with late-onset depression.
A key clinical insight is the risk-stratification model, which combined anxiety history, comorbidities, socioeconomic status, and selected age/treatment factors. Survivors in the highest-risk tertile had double the cumulative incidence of depression compared with low-risk survivors. Importantly, while non-Hispanic Black, Hispanic, and Asian survivors had statistically lower hazard ratios for depression, they were paradoxically more likely to be classified as high-risk due to greater socioeconomic vulnerability and comorbidity burden—raising concerns about underdiagnosis and disparities in mental-health care.
Clinical Implications for Physicians
- Screen beyond the active treatment phase. Depression may emerge many years after remission and should be part of routine survivorship care, particularly in older adults.
- Prioritize high-risk groups—those with prior anxiety, multimorbidity, socioeconomic challenges, or (in prostate cancer) prior radiotherapy/ADT.
- Address structural barriers. Dual-eligible patients may face access obstacles; proactive referrals and care coordination are essential.
- Monitor prostate cancer survivors closely, especially those with prolonged ADT exposure.
Key Messages for Patients
- Experiencing depression years after cancer treatment is common and treatable.
- People with multiple health conditions, financial stress, or a history of anxiety may benefit from early and regular emotional-health check-ins.
- Survivors should feel empowered to seek help immediately if mood, sleep, or energy changes develop—these symptoms are not unusual, and effective treatments exist.
Final Thought:
We have extensive evidence that exercise is an effective anti-depression therapy. This publication strongly supports cancer patients being referred to Exercise Oncology Programs as a way of preventing and/or treating depression during active treatment and long-term survivorship.
Reference: JAMA Network Open. 2025;8(11):e2544812. doi:10.1001/jamanetworkopen.2025.44812 November 26, 2025
